Changes in weight, plasma lipids, and glucose in adults treated with ziprasidone: A comprehensive analysis of Pfizer-initiated clinical trials

Journal of Clinical Psychiatry

Volumn 73, Issue 6, 2012, Pages

  Pappadopulos, Elizabeth ^a   Newcomer, John W ^b   Kolluri, Sheela ^a  

^a PFIZER INC   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL; ZIPRASIDONE;

ADULT; AGED; ARTICLE; BIPOLAR DISORDER; CHOLESTEROL BLOOD LEVEL; CONTROLLED CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; MONOTHERAPY; POST HOC ANALYSIS; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; WEIGHT CHANGE; WEIGHT GAIN;

EID: 84863551431     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.10r06802     Document Type: Article

References (30)

1. Casey DE, Haupt DW, Newcomer JW, et al. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry. 2004;65(suppl 7):4-18, quiz 19-20. PubMed
2. Colton CW, Manderscheid RW. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis. 2006;3(2):A42. PubMed
3. Jeste DV, Gladsjo JA, Lindamer LA, et al. Medical comorbidity in schizophrenia. Schizophr Bull. 1996;22(3):413-430. PubMed (Pubitemid 26295345)
4. Miller BJ, Paschall CB 3rd, Svendsen DP. Mortality and medical comorbidity among patients with serious mental illness. Psychiatr Serv. 2006;57(10):1482-1487. doi:10.176/api.ps.57.10.1482 PubMed (Pubitemid 44671660)
5. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry. 2007;64(10):1123-1131. doi:10.101/archpsyc.64.10.123 PubMed (Pubitemid 47529346)
6. Curkendall SM, Mo J, Glasser DB, et al. Cardiovascular disease in patients with schizophrenia in Saskatchewan, Canada. J Clin Psychiatry. 2004; 65(5):715-720. doi:10.408/JCP.v65n0519 PubMed
7. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19(suppl 1): 1-93. doi:10.2165/023210-2051901-01 PubMed (Pubitemid 40677047)
8. Allison DB, Fontaine KR, Heo M, et al. The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry. 1999;60(4):215-220. doi:10.408/JCP.v60n0402 PubMed (Pubitemid 29193917)
9. Goff DC, Sullivan LM, McEvoy JP, et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res. 2005;80(1):45-53. doi:10.1016/j.schres.205.08.010 PubMed (Pubitemid 41587462)
10. McCreadie RG; Scottish Schizophrenia Lifestyle Group. Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study. Br J Psychiatry. 2003;183(6):534-539. doi:10.192/bjp.183.6.534 PubMed
11. McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005;80(1):19-32. doi:10.1016/j.schres.205.07.014 PubMed (Pubitemid 41587460)
12. Subramaniam M, Chong SA, Pek E. Diabetes mellitus and impaired glucose tolerance in patients with schizophrenia. Can J Psychiatry. 2003;48(5):345-347. PubMed (Pubitemid 36841274)
13. Birkenaes AB, Opjordsmoen S, Brunborg C, et al. The level of cardiovascular risk factors in bipolar disorder equals that of schizophrenia: a comparative study. J Clin Psychiatry. 2007;68(6):917-923. doi:10.408/JCP. v68n0614 PubMed (Pubitemid 47015492)
14. Correll CU, Frederickson AM, Kane JM, et al. Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics. Bipolar Disord. 2008; 10(7):788-797. doi:10.1/j.139-5618.208.0625.x PubMed
15. Kilbourne AM, Cornelius JR, Han X, et al. Burden of general medical conditions among individuals with bipolar disorder. Bipolar Disord. 2004;6(5):368-373. doi:10.1/j.139-5618.204.0138.x PubMed (Pubitemid 39345287)
16. McElroy SL, Frye MA, Suppes T, et al. Correlates of overweight and obesity in 644 patients with bipolar disorder. J Clin Psychiatry. 2002;63(3):207-213. doi:10.408/JCP.v63n0306 PubMed (Pubitemid 34407079)
17. Simon GE, Von Korff M, Saunders K, et al. Association between obesity and psychiatric disorders in the US adult population. Arch Gen Psychiatry. 2006;63(7):824-830. doi:10.101/archpsyc.63.7.824 PubMed
18. Newcomer JW, Hennekens CH. Severe mental illness and risk of cardiovascular disease. JAMA. 2007;298(15):1794-1796. doi:10.101/jama.298.15. 1794 PubMed (Pubitemid 47598448)
19. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156(11):1686-1696. PubMed (Pubitemid 29517559)
20. Folks DG, Lombardo I, Loebel AD, et al. Effect of ziprasidone on weight and metabolic parameters at various fixed doses in patients with schizophrenia or schizoaffective disorder. Presented at: American Psychiatric Association Annual Meeting; May 19-24, 2007; San Diego, CA. Poster NR512.
21. Newcomer JN, Mandel FS, Lombardo I. Ziprasidone treatment effects on weight and lipids in patients with metabolic risk. Presented at: American Psychiatric Association Annual Meeting; May 3-8, 2008; Washington, DC. Poster NRA 052.
22. Weiden PJ, Simpson GM, Potkin SG, et al. Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia. J Clin Psychiatry. 2003;64(5):580-588. doi:10.408/JCP.v64n0514 PubMed (Pubitemid 36618289)
23. Weiden PJ, Newcomer JW, Loebel AD, et al. Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone. Neuropsychopharmacology. 2008;33(5):985-994. doi:10.1038/sj.np.1301482 PubMed (Pubitemid 351367540)
24. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27(2):596-601. doi:10.237/diacare.27.2.596 PubMed
25. Daniel DG, Zimbroff DL, Potkin SG, et al Ziprasidone Study Group. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Neuropsychopharmacology. 1999;20(5):491-505. doi:10.1016/S0893-13X(98)090-6 PubMed
26. Keck PJ Jr, Buffenstein A, Ferguson J, et al. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology (Berl). 1998;140(2):173-184. doi:10.107/s021305075 PubMed (Pubitemid 28538477)
27. Keck PEJ Jr, Versiani M, Potkin S, et al. Ziprasidone in Mania Study Group. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry. 2003;160(4):741-748. doi:10.176/api.ajp.160.4.741 PubMed (Pubitemid 41079608)
28. Potkin SG, Keck PE Jr, Segal S, et al. Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial. J Clin Psychopharmacol. 2005;25(4):301-310. doi:10.1097/01.jcp.0169068.3432.70 PubMed (Pubitemid 41065070)
29. Lieberman JA, Stroup TS, McEvoy JP, et al Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-1223. doi:10.1056/NEJMoa05168 PubMed (Pubitemid 41345943)
30. Ogden CL, Carroll MD, Curtin LR, et al. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA. 2006;295(13): 1549-1555.